Verrica unveils positive data from VP-102 study in molluscum treatment
Category: #health  By Mateen Dalal  Date: 2020-01-20
  • share
  • Twitter
  • Facebook
  • LinkedIn

Verrica unveils positive data from VP-102 study in molluscum treatment
  • Findings from the study are being produced at the 17th Annual Winter Clinical Dermatology Conference in Kohala Coast
  • The data indicated a considerable increase in the percentage of patients with lesion clearance in VP-102 group

Verrica Pharmaceuticals Inc. – a U.S. based clinical-stage dermatology firm that develops medical solutions for viral skin diseases has reportedly announced positive results from a post-hoc pooled analysis of the vital Phase 3 CAMP clinical trials that assess the effectiveness and safety of VP-102 in the treatment of molluscum contagiosum.  

Apparently, the new results indicated that the total percentage of patients with zero infections or injuries was statistically considerably higher in the VP-102 group as compared to the vehicle, across all body regions.

According to Lawrence Eichenfield, MD, Chief of Pediatric and Adolescent Dermatology at Rady’s Children’s Hospital and primary investigator of the VP-102 stage 3 molluscum study was reportedly quoted stating that the analysis of the study is vital since it advises that the investigational treatment of molluscum can significantly lead to complete clearance, despite which part of the body is infected.

If approved, the medication can be a viable choice for physicians as they will have the option to treat even the most sensitive areas such as the neck, head and groin, he further added.

For the record, in the analysis of the CAMP studies, the intent-to-treat patient population had prevailing molluscum lesions in certain areas such as the neck, chest and abdomen, groin, upper extremities, back or buttocks and lower extremities. The effectiveness was calculated as per the percentage of subjects with complete clearance of infections in every location based on visits.

The data showcased a significant increase in the percentage of lesion clearance towards the end of the trial i.e. Day 84 across the entire body region calculated among the patients who received VP-102 as compared to vehicle.  

During the research, VP-102 safety results showcased similar adverse event rates across the entire body regions. Cases of application site Treatment-Emergent Adverse Events were calculated on the basis of pre-specified subset of application site reactions registered during or after Treatment Visit 1 and before the second Visit. The most common treatment-emergent adverse events consist of application site vesicles, dryness, pain, edema, pruritus, scab, erythema and discoloration.

 

Source Credits: https://investors.verrica.com/news-releases/news-release-details/verrica-pharmaceuticals-announces-presentation-positive-data-new

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

Mateen has completed his Bachelor’s degree in electronics and telecommunication engineering, post which he lent his proficiency to the industry, working as a quality and test engineer. Drawn intricately toward the field of content creation however, Mateen soon switc...

Read More

More News By Mateen Dalal

TPG Rise Climate Fund raises $5.4Bn to support new climate solutions
TPG Rise Climate Fund raises $5.4Bn to support new climate solutions
By Mateen Dalal

TPG Rise Climate Fund, the climate investing fund of TPG’s global impact investing platform TPG Rise, has recently raised its first close of $5.4 billion, bringing together an exclusive blend of funding from some of the top institutional invest...

Baby nutrition firm ByHeart nabs $90Mn in Series B funding round
Baby nutrition firm ByHeart nabs $90Mn in Series B funding round
By Mateen Dalal

ByHeart, a fully integrated infant nutrition company, has reportedly secured $90 million in Series B funding which the company plans to use for the launch of its baby formula and support the development of its pipeline of nutrition items for chi...

UAE extends travel ban for Indians amid strict COVID-19 guidelines
UAE extends travel ban for Indians amid strict COVID-19 guidelines
By Mateen Dalal

United Arab Emirates (UAE) has reportedly extended travel ban for individuals travelling from India and several other south Asian countries on the pretext of COVID-19 guidelines. As reported by Etihad Airlines, the ban will be followed till 31st July...